Impact of a VI-polysaccharide conjugate vaccine in preventing Typhoid Fever in an endemic setting, Lalitpur, Nepal by Shakya, M

“…</p> <p>In this phase III participant-observer-blind randomized controlled trial, children aged 9 months to under-16 years old, were individually randomized (1:1) to either receive the TCV (Typbar-TCV, Bharat Biotech) or a capsular group A meningococcal conjugate vaccine (MenA) as control, and were followed-up for two years.…”

Immunogenicity and efficacy of conjugated and unconjugated Vi-polysaccharide vaccines in the prevention of typhoid fever by Jin, C

“…</p> <p>The findings from this study represent the first efficacy results and comprehensive assessment of humoral immunity for the only WHO prequalified TCV - Vi-TT (Typbar-TCV, Bharat Biotech). These results contributed to a change in global health policies and funding prioritisation for TCVs. …”